Clinical Trial Update: A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B [Phase 3]

View source ↗

Summary

This is a Phase 3 randomized trial evaluating whether 48 weeks of pegylated interferon alfa-2a can achieve loss of HBsAg (HBsAg negativation) in patients with c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegylated Interferon Alpha-2a (pegylated interferon alfa-2a)

Snippet

Sponsor: ANRS, Emerging Infectious Diseases | Conditions: Chronic Hepatitis B, AgHbs Negativation | Phase 3 | Status: UNKNOWN